Follow the Prostatype Genomics AB stock price and the full insider trade history of the company, a listed equity based in Finland. Shares are listed on FI FI, under the authority of FIN-FSA. Operating in the Health Care sector, Prostatype Genomics AB has recorded 4 insider filings. Market capitalisation: €41.3m. The latest transaction was disclosed on 7 October 2025 (Purchase). Among the most active insiders: Anders Lundberg. All data is accessible without an account.
4
Insider Decl.
0
Thresholds
€97,219
4 ops.
Buy Volume
·
0 ops.
Sell Volume
24Σ signal
Buys €97,219· Sells
Fundamental score
Ranked 22,420 of 25,921 companies
25.3
score / 100
Value
1
Quality
50
FCF yld-134%
Earn yld-160%
EV/EBITDA·
ROE-148%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.